|dc.description.abstract||Retinal ganglion cells (RGCs) are essential for human visual perception, as they mediate the transfer of visual information from the eye to the brain. In the event of RGC death, as happens in diseases such as glaucoma, vision is permanently lost because the mammalian central nervous system (CNS) does not regenerate. In order to find novel treatments for the RGC diseases, a number of different research approaches have been undertaken. One relatively recent approach involves the use of pluripotent stem cell (PSC) technologies. As human PSCs can be differentiated to the RGC lineage, it has become possible to utilize human RGCs for drug discovery, disease modeling, or transplantation experiments to attempt visual system recovery.
The field of PSC differentiation to RGCs has been steadily developing, but many hurdles remain. Initial reports involved co-culture of mouse stem cells with primary embryonic retinal cells or conditioned media, and yielded only small numbers of cells. Evolution of ocular stem cell biology over the past few years has greatly improved the technology for generation of three-dimensional optic vesicles that develop all of the retinal layers, including the RGC layer. Although such reports were very encouraging, these studies failed to demonstrate that RGCs could be isolated from culture and deeper profiles of the RGCs were missing. Here, we describe a novel, simplified protocol for RGC differentiation from human PSCs. We took advantage of recently developed CRISPR-Cas9 technologies to genetically engineer a stem cell reporter line for RGCs based on the BRN3B/POU4F2 gene. Using this line, we developed a fluorescence-activated cell sorting (FACS) protocol that yields highly purified RGCs, and we subsequently characterized the purified cells in terms of their expression pattern of RGC-associated genes and other cellular properties. Despite the power of FACS to provide purified populations of fluorescent RGCs, FACS-based purification schemes also have their limitations. A main limitation is the relatively slow speed and restricted throughput of FACS. In order to get around these limitations, we developed an alternative approach by genetically engineering a unique cell surface antigen driven by the BRN3B gene into stem cells, allowing us to isolate populations of pure differentiated RGCs by affinity purification in an efficient, large scale, and time saving manner that makes possible the use of human RGCs in a variety of studies including high throughput drug discovery screens. In addition to developing this new RGC purification strategy, which has implications for developing improved systems for the purification of a wide variety of different cell types, we have also optimized our initial differentiation protocol by manipulating known signaling pathways via small molecule supplementation to guide the cells toward a retinal cell fate.
In addition to developing and characterizing improved stem cell-based approaches for generating RGCs, we have also been pursuing the generation of RGCs from non-stem cell lines through trans-differentiation and direct reprogramming. Through this work, we have identified a combination of four transcription factors that can directly reprogram the human retinal pigment epithelium (RPE) cell line ARPE19 into RGC-like cells. Expression of ATOH7, BRN2, BRN3B, and MYT1 in ARPE19 cells transformed their morphology to a neuronal phenotype and induced the expression of pan-neuronal and RGC-associated genes. Moreover, when overexpressed in stem cells undergoing retinal differentiation, these factors were able to boost the percentage of cells differentiating to the RGC lineage, an effect that could be further increased by our previously identified small molecules.
Lastly, we discuss the development of a new method to enhance homology directed repair for the purpose of generating reporter lines in an easier and more routine way. Taken together, these studies provide powerful tools for the use of stem cell technology to study RGC differentiation and biology, and the mechanisms of RGC injury and cell death. Additionally, they provide the means to provide well-characterized and large supplies of RGCs for drug discovery screens and lay the groundwork for possible future cell-based therapeutic approaches for treatment of vision loss and blindness from glaucoma and other forms of optic nerve disease.||